Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
| The following video is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 . |
CHICAGO –Terence Rooney, MD, senior medical director, Lilly Bio-Medicines, discusses updated baricitinib safety data presented at the 2018 ACR/ARHP Annual Meeting, held October 19-24, in Chicago, Illinois.
Baricitinib is approved by the FDA to treat adults with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonists.
Disclosures: Dr Rooney is employed by Eli Lilly and Compay.
This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.
